Eli Lilly Sales Rebates and Discounts decreased by 1.4% to $17.38B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 50.6%, from $11.54B to $17.38B. Over 5 years (FY 2020 to FY 2025), Sales Rebates and Discounts shows an upward trend with a 24.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase may signal higher competitive pressure or changes in payer mix, impacting net realized pricing.
Accrued liabilities representing estimated rebates, chargebacks, and discounts owed to wholesalers, pharmacy benefit man...
Highly specific to the pharmaceutical and healthcare sectors; essential for comparing net pricing power.
sales_rebates_and_discounts| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.04B | $7.19B | $6.85B | $6.77B | $7.99B | $8.57B | $8.78B | $9.53B | $10.39B | $11.52B | $11.69B | $9.43B | $12.45B | $12.43B | $11.54B | $11.55B | $14.54B | $17.62B | $17.38B |
| QoQ Change | — | +2.1% | -4.7% | -1.1% | +18.1% | +7.2% | +2.5% | +8.5% | +9.0% | +10.9% | +1.4% | -19.3% | +32.0% | -0.1% | -7.2% | +0.1% | +25.9% | +21.2% | -1.4% |
| YoY Change | — | — | — | — | +13.6% | +19.2% | +28.3% | +40.8% | +30.0% | +34.5% | +33.1% | -1.0% | +19.8% | +7.9% | -1.3% | +22.5% | +16.8% | +41.8% | +50.6% |
We use cookies for analytics. See our Privacy and Cookie Policy.